TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent.

Для цитирования: Gangat Naseema, Warraich Momna, Kumar Sudhesh, Fatima Mahnoor, McCullough Kristen, Begna Kebede H, Al-Kali Aref, Patnaik Mrinal M, Hogan William J, Mangaonkar Abhishek, Saliba Antoine N, Torghabeh Mehrdad Hefazi, Alkhateeb Hassan, Shah Mithun V, Foran James M, Badar Talha, Palmer Jeanne M, Yi Cecilia Arana, Pardanani Animesh, Tefferi Ayalew. TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent.. American journal of hematology. 2026. DOI: 10.1002/ajh.70248.